Phase 1 trial starts next quarter.
In the meantime we will have the following newsflow leading into :
The full PK (whatever that is)
Genotoxicity study results
Safety pharmacology study results
Toxicokinetic study results
Also commentary on the optimistation of the manufacturing processes.
ARGENICA THERAPEUTICS LIMITED IPO Analysis, page-82
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AGN (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
83.0¢ |
Change
-0.015(1.78%) |
Mkt cap ! $102.6M | |||
| Open | High | Low | Value | Volume |
| 84.5¢ | 84.5¢ | 80.0¢ | $64.05K | 78.35K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 124 | 83.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 86.0¢ | 6500 | 1 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| AGN (ASX) Chart |